Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Di Scala

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Statistics in Medicine|September 8, 2011
Time-to-event analysis with treatment arm selection at interimL Di Scala, E Glimm
Statistics in Medicine|January 11, 2013
Collection, synthesis, and interpretation of evidence: a proof-of-concept study in COPDL Di Scala, J Kerman, B Neuenschwander
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 25, 2009
Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitorsJ-C Soria, F A Shepherd, J-Y Douillard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2017
An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinomaS Temam, J Spicer, F Farzaneh, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Statistics in Medicine|September 8, 2011
Time-to-event analysis with treatment arm selection at interimL Di Scala, E Glimm
Statistics in Medicine|January 11, 2013
Collection, synthesis, and interpretation of evidence: a proof-of-concept study in COPDL Di Scala, J Kerman, B Neuenschwander
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 25, 2009
Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitorsJ-C Soria, F A Shepherd, J-Y Douillard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2017
An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinomaS Temam, J Spicer, F Farzaneh, et al.
Pageof 1